Related Experiment Video
Updated: May 22, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Drug-induced interstitial pneumonitis due to low-dose lenalidomide
Kei Kunimasa1, Tomoaki Ueda, Machiko Arita
1Department of Respiratory Medicine, Kurashiki Central Hospital, Japan. kk11900@kchnet.or.jp
Abstract:
Lenalidomide is a second-generation immunomodulatory drug that has been approved to treat relapsed or refractory multiple myeloma. Here, we describe a patient who was treated with a low dose of lenalidomide (5 mg/day on days 1-21 of a 28-day cycle) because the standard dose of bortezomib was too toxic and adverse events persisted. However, he developed fever, dyspnea, hypoxia and pulmonary infiltrates. The results of an extensive workup for other causes including infections were negative and the final diagnosis was lenalidomide-induced interstitial pneumonitis. This is the first case report of lenalidomide-induced pneumonitis in a Japanese patient.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug toxicity: Idiosyncratic Reactions
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Drug Toxicity: Risk factors
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents